A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.

about

Cancer nanobiotechnolgy.

P2860

Q54939079-C4C1C89F-E798-472D-BDE0-CBD1EAB8B43F

P2860

A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.

Item

http://www.wikidata.org/entity/Q38701979

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A versatile nanoplatform for s ...... treat human esophageal cancer.

@en

type

Item

label

A versatile nanoplatform for s ...... treat human esophageal cancer.

@en

prefLabel

A versatile nanoplatform for s ...... treat human esophageal cancer.

@en

P1476

A versatile nanoplatform for s ...... treat human esophageal cancer

@en

P2093

De-Jiu Kong

http://www.w3.org/2001/XMLSchema#string

Jun-Qiang Yang

http://www.w3.org/2001/XMLSchema#string

Kit S Lam

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

She-Gan Gao

http://www.w3.org/2001/XMLSchema#string

Tzu-Yin Lin

http://www.w3.org/2001/XMLSchema#string

Xiao-Cen Li

http://www.w3.org/2001/XMLSchema#string

Xiao-Chen Hu

http://www.w3.org/2001/XMLSchema#string

Xin-Shuai Wang

http://www.w3.org/2001/XMLSchema#string

Xue-Zhen Ding

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2016

Clinical pharmacokinetics of docetaxel.

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.

Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial.

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment.

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

P2888

aps.2017.43

P304

931-942

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/APS.2017.43

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yoshihiro Izumiya

P577

2017-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085729772

http://www.w3.org/2001/XMLSchema#string

P698

28552907

http://www.w3.org/2001/XMLSchema#string

P932

5520194

http://www.w3.org/2001/XMLSchema#string

A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.

about

P2860

P2860

A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932